Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
Status: Recruiting
Location: See all (7) locations...
Study Type: Observational
SUMMARY
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:
• Age ≤ 18 years at time of transplant listing
• Subject is within 10-50 days post-orthotopic heart transplant at time of enrollment.
• Planned follow-up at the transplant center for a minimum of one-year.
• Caregiver able and willing to comply with the study visit schedule, study procedures, and study requirements.
Locations
United States
Colorado
Children's Hospital Colorado
RECRUITING
Aurora
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING
Chicago
Michigan
University of Michigan
RECRUITING
Ann Arbor
New York
Columbia University
RECRUITING
New York
Pennsylvania
University of Pittsburgh
RECRUITING
Pittsburgh
Tennessee
Vanderbilt University
RECRUITING
Nashville
Texas
Texas Children's Hospital
RECRUITING
Houston
Contact Information
Primary
Palak Shah, MD
optima@northwestern.edu
312-694-7805
Time Frame
Start Date: 2025-02-06
Estimated Completion Date: 2029-10-01
Participants
Target number of participants: 150
Related Therapeutic Areas
Sponsors
Leads: Northwestern University